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Aim Thrombolytic therapy induces faster clot dissolution than anticoagulation in patients with acute pulmonary embolism
(PE) but is associated with an increased risk of haemorrhage. We reviewed the risks and benefits of thrombolytic
therapy in the management of patients with acute PE.
Methods
and results
We systematically reviewed randomized controlled studies comparing systemic thrombolytic therapy plus anticoagula-
tion with anticoagulation alone in patients with acute PE. Fifteen trials involving 2057 patients were included in our meta-
analysis. Compared with heparin, thrombolytic therapy was associated with a significant reduction of overall mortality
(OR; 0.59, 95% CI: 0.36–0.96). This reduction was not statistically significant after exclusion of studies including high-
risk PE (OR; 0.64, 95% CI: 0.35–1.17). Thrombolytic therapy was associated with a significant reduction in the combined
endpoint of death or treatment escalation (OR: 0.34, 95% CI: 0.22–0.53), PE-related mortality (OR: 0.29; 95% CI: 0.14–
0.60) and PE recurrence (OR: 0.50; 95% CI: 0.27–0.94). Major haemorrhage (OR; 2.91, 95% CI: 1.95–4.36) and fatal
or intracranial bleeding (OR: 3.18, 95% CI: 1.25–8.11) were significantly more frequent among patients receiving
thrombolysis.
Conclusions Thrombolytic therapy reduces total mortality, PE recurrence, and PE-related mortality in patients with acute PE. The de-
crease in overall mortality is, however, not significant in haemodynamically stable patients with acute PE. Thrombolytic
therapy is associated with an increase of major and fatal or intracranial haemorrhage.
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Introduction
Pulmonary embolism (PE) is a common disease occurring in 60–112
per100 000people/year.1,2 According toprospectivecohort studies,
the case fatality rate in the acute phase ranges from 7 to 11%. 3 –5
Nevertheless, acutePE represents awide spectrumof clinical presen-
tations with varying clinical outcomes. To guide the management of
acute PE, the European Society of Cardiology6 and the American
Heart Association7 have proposed a three-level risk stratification
scheme based on haemodynamic status and the presence of
right ventricular dysfunction (RVD) or myocardial injury. High-risk
(or massive) PE is defined as an acute PE with sustained systemic ar-
terial hypotension. Intermediate-risk (or submassive)PE is defined by
the presence of RVD or injury in the absence of arterial hypotension.
Finally, low-risk PE is defined by the absence of hypotension and of
markers of RVD or injury.
In 1970, the first randomized trial comparing urokinase with
heparin for patients with PE was published8 and 7 years later,
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streptokinase was approved by the US Food and Drug Administra-
tion (FDA) for the treatment of high-risk PE. Since then, thrombolytic
therapy has been shown to induce faster clot dissolution and haemo-
dynamic improvement compared with heparin alone.9 –13 However,
more than three decades later, the role of thrombolytic therapy in
the treatment of patients with non-high-risk PE remains controver-
sial. Previous meta-analyses have failed to demonstrate a positive
impact of thrombolytic treatment on total mortality and suggested
an increase in major haemorrhage.14– 16 These studies were limited
by the relatively small number of patients included in randomized
trials.
Current guidelines recommend thrombolytic therapy for patients
with high-risk PE in the absence of contraindications.6,7,17 Thromb-
olysis is not recommended on a routine basis for patients with
intermediate-risk PE but may be considered following individual
risk-to-benefit analysis. More recently, further evidence regarding
the role of thrombolytic therapy for patients with acute PE was pub-
lished,13,18 including the large multicentre PEITHO trial.19
We performed a systematic review and meta-analysis of rando-
mized controlled trials comparing anticoagulation plus systemic
thrombolysis with anticoagulation alone for patients with acute PE.
We also sought to identify potential subgroups of patients with a fa-
vourable risk–benefit ratio and planned to separately analyse studies
according to their criteria of PE severity.
Methods
Search strategy, study selection, data extraction, and analysis were
performed according to a pre-defined protocol.
Search strategy
Two authors (C.M. and G.J.) systematically searched Medline, Embase
and the Cochrane Controlled Trials registry using the following key
words: (pulmonary embolism AND [thrombolysis OR thrombolytic therapy
OR streptokinase Or urokinase OR tenecteplase OR desmoteplase OR rete-
plase OR tissue plasminogen activator]) The detailed search strategy is avail-
able in Supplementary material online and was last updated on 16
February 2014. To ensure a comprehensive literature search, we exam-
ined reference lists from retrieved articles and reference literature
(guidelines and systematic reviews) and questioned experts in PE for pos-
sible published or unpublished missing studies.
Study selection and data extraction
We included randomized controlled trials comparing a thrombolytic
agent [streptokinase, urokinase, recombinant tissue plasminogen
activator (alteplase), desmoteplase, reteplase, or tenecteplase] adminis-
tered systemically by the i.v. route and heparin (unfractionated or
low-molecular-weight heparin) with heparin alone in patients with
acute PE. Studies comparing two regimens of thrombolytic therapy,
and those using mechanical thrombectomy along with thrombolytic
treatment or local catheter-delivered thrombolysis, were excluded.
Two investigators (C.M. and G.J.) independently evaluated studies for
possible inclusion. Non-relevant studies were excluded based on title
and abstract. For potentially relevant studies, full-text was obtained and
two investigators (C.M. and G.J.) independently assessed study eligibility
and extracted the data on study design, patient characteristics, and
outcomes. Disagreement about study inclusion or data extraction was
resolved by consensus or by discussion with a third author (A.P.).
Outcomes and measurements
The primaryefficacyoutcome was early all-cause mortality (in hospital or
within 30 days of inclusion). Three secondary efficacy outcomes were
considered: recurrent PE confirmed by a validated diagnostic examin-
ation; death related to PE and the combination of all-cause death or clin-
ical deterioration requiring rescue treatment (vasopressors, mechanical
ventilation, cardio-pulmonary resuscitation, systemic rescue thromboly-
sis, or embolectomy).
Two safety outcomes, major bleeding and fatal or intracranial haemor-
rhage, were analysed. Major bleeding was defined according to the Inter-
national Society of Thrombosis and Haemostasis (ISTH)20 when
sufficient information was available. In the other cases, definitions from
the original studies were used. Two authors (C.M. and G.J.) independently
extracted the patient characteristics and outcomes from retrieved
studies.
Study quality assessment
Quality of included studies was assessed using quality criteria developed
by Jadad et al.21 evaluating thequalityof randomization, blinding and hand-
ling of exclusion and attrition. Two investigators (C.M. and G.J.) assessed
study quality independently. Disagreements were resolved by consensus.
Data analysis
All analyses were performed on data reported according to the
intention-to-treat principle. Pooled odds ratios (ORs) were obtained
using the Mantel–Haenszel method given the small sample size in
some studies and the low prevalence of events.22 A continuity correction
of 0.5 was applied for studies without event in one arm. Fixed effect
models were used because of the low heterogeneity. The significance
level was set at 0.05. The heterogeneity wasmeasuredby the I2 statistic.23
Potential heterogeneity factorswereexploredbypre-specified subgroup
analyses including: studies excluding high-risk PE, studies including (not
exclusively) high-risk PE, studies limited to intermediate-risk PE
(defined by the presence of RVD on imaging studies, and/or by elevated
cardiac biomarkers), studies including low- and intermediate-risk PE, ex-
clusion of older patients, and the type of thrombolytic agent used. For the
safety outcomes, subgroup analyses were performed according to the
type of a diagnostic procedure (invasive vs. non-invasive). Post hoc supple-
mentary subgroup analyses were performed to explore the impact of the
length of follow-up (14 days or less vs. 15–30 days) and the time from the
onset of symptoms to inclusion (superior or inferior to 1 week). Finally,
we performed a meta-regression to explore a potential variation of the
odds ratios over time using the logarithm of the odds ratios over years
of publication.
Sensitivity analyses were conducted to check the robustness of the
pooled ORs by removing each study one-by-one, by excluding lower
quality studies (Jadad score ,4) and by applying several continuity cor-
rections (correction from 0.01 to 0.5 by step of 0.1) and treatment arm
correction.24 Additionally, an exact method was applied. The advantage
is to account for studies without event in both arms. Publication bias was
assessed using inspection of the funnel plot, Egger’s test, and the trim and
fill method.25 The R package ‘meta: Meta analysis with R, version 1.6-1’
and StatXact-8.0.0 (Cytel, Inc., Cambridge, MA, USA) was used for
these analyses.
Results
Study selection and characteristics
The search retrieved a total of 4338 references, among which 940
duplicates were identified. Of the 3398 remaining articles, 3169
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were excluded based on title and abstract (Figure 1). Full-text was
obtained for the remaining 229 articles. Of these, 29 did not
contain original data, 58 did not study systemic thrombolysis, 96
were non-randomized trials, 33 compared two thrombolytic regi-
mens, and 13 satisfied the inclusion criteria. Two additional studies
were identified by manual search.19,26 Inter-readers agreement was
high (Kappacoefficient0.99). The main characteristics of the included
studies are displayed in Table 1.
Study quality/risk of bias
The qualityof randomization wasconsideredadequate in nine studies
(Supplementary material online, Table S1). Both patients and investi-
gators were blinded to the treatment arm in eight studies. Among the
15 included studies, 11 were considered of good quality (Jadad score
4–5), one of fair quality, and three of poor quality. Inclusion criteria
differed among studies: four studies 8,19,27– 29 included patients with
high-risk PE, and three specifically included patients with
intermediate-risk PE 10,13,19(Table 1). Six studies used an upper age
limit as an exclusion criteria and the mean age of included patients
varied from 5330 to 68 years.10 Bleeding complications could be
extracted according to the ISTH definition in all studies but
three8,29,31 in which data were extracted according to the authors’
definition of major haemorrhage. Finally, the outcome ‘death or
treatment escalation’ was extracted from the case description avail-
able in the published studies, but this outcome was specifically pre-
defined in only five studies.8,10,19,26,31
Overall mortality
All 15 studies including 2057 patients reported early (≤30 days) all-
cause mortality. The reported mortality was 2.3% (24/1033) in the
thrombolysis group and 3.9% (40/1024) in the control group.
Thrombolytic therapy was associated with a significant reduction
of early mortality (pooled OR: 0.59; 95% CI: 0.36–0.96, P ¼ 0.03;
Figure 2). No heterogeneity was observed among studies (I2 ¼ 0%).
After exclusion of studies including high-risk PE, treatment effect
was similar, but statistical significance was lost (OR: 0.64; 95% CI:
Figure 1 Study flow chart.
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Table 1 Characteristics of included studies
First author
and year of
publication
Number
of patients
Eligibility Severity
criteria
High-risk PE
included
Thrombolysis Control Age limit
(years)
Follow-upa Invasive
angiography
Primary
endpoint
Becattini (2010) 58 Acute PE,10 days RVD No Tenecteplase 30–50 mg
plus heparin
Heparin 85 30 days No 24 h RVDb
Dalla Volta (1992) 36 Acute PE,10 days Miller score
.11
No Alteplase 100 mg/2 h plus
heparin
Heparin 80 30 days 100% Pulmonary
perfusionc
Dotter (1979) 31 Acute PE No Yes Streptokinase 2–11
MIU 18–72 h
Heparin No 7 days 100% Pulmonary
perfusionc
Fasullo (2011) 72 Acute PE,6 h RVD No Alteplase 100 mg/2 h plus
heparin
Heparin 75 10 days No RVDb
Goldhaber (1993) 101 Acute PE,14 days No No Alteplase 100 mg/2 h plus
heparin
Heparin No 14 days 21% RVDb
Jerjes-Sanchez (1995) 8 Acute PE,14 days Massive Yes Streptokinase 1.5 MIU/2 h Heparin No In-hospital No RVD, pulmonary
perfusiond
Kline (TOPCOAT)
(2013)
83 Acute PE RVD or
hypoxaemia
No Tenecteplase 30–50 mg/2 h
plus enoxaparin
LMWH No 5 days NA Composite clinical
outcome
Konstantinides
(MAPPET) (2002)
256 Acute PE,4 days RVD or pHTA No Alteplase 100 mg/2 h plus
heparin
Heparin 80 30 days/
in-hospital
16% Death or treatment
escalation
Levine (1990) 58 Acute PE,14 days No No Alteplase 0.6 mg/kg/2 min Heparin No 10 days 67% Pulmonary
perfusiond
Ly (1978) 20 Acute PE,5 days .1 lobe
d
Yes Streptokinase 72 h Heparin 70 10 days 100% Pulmonary
perfusionc
Marini (1988) 30 Acute PE,7 days .9 segments
d
No Urokinase 2.4–3.3 MIU
/12–72 h
Heparin 72 7 days 100% Pulmonary
perfusiond
Meyer (PEITHO)
(2014)
1005 Acute PE,15 days RVD and
elevated
troponin
No Tenecteplase 30–50 mg
plus heparin
Heparin No 7 days 1.4% Death or
haemodynamic
collapse
Sharifi (2013) 121 Acute PE,10 days ≥2 lobesd No Alteplase 50 mg/
2 h + heparin
Heparin or
LMWH
No In-hospital No Pulmonary
hypertensionb
Stein (PIOPED) (1990) 13 Acute PE,7 days ≥ 1 lobe or ≥ 2
segments
d
No Alteplase 40–80 mg/
40–90 min + heparin
Heparin No 7 days 100% Pulmonary
perfusionc
UPET (1970) 160 Acute PE,5 days No Yes Urokinase 12 h Heparin No 14 days 100% Pulmonary
perfusionc,d
PE, pulmonary embolism; RVD, right ventricular dysfunction; LMWH, low-molecular-weight heparin; MIU: million units, NA, not available, pHTA, pulmonary hypertension.
aFollow-up for overall mortality.
bEchocardiography.
cPulmonary angiography.
dBased on ventilation-perfusion scintigraphy. C
.M
artietal.
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0.35–1.17). The pooled ORs were similar in studies including high-
risk PE (OR: 0.48; 95% CI: 0.2–1.15) and studies including only
intermediate-risk PE (0.42; 95% CI: 0.17–1.03), whereas the
pooled OR was close to one in studies including both low- and
intermediate-risk PE (0.96; 95% CI: 0.41–2.24) (Table 2 and
Figure 2). Subgroup analysis based on the thrombolytic regimen did
not show any significant differences between alteplase (OR: 0.64;
95% CI: 0.29–1.41), tenecteplase (OR: 0.65; 95% CI: 0.26–1.64)
or older thrombolytics (OR: 0.48; 95% CI: 0.20–1.15) (P ¼ 0.86).
Pulmonary embolism-related mortality
Pulmonary embolism -related mortality was reported in 13
studies,8,10 – 13,19,26 – 32 including 1776 patients (Supplementary
material online, Figure S1). The reported PE-related mortality
was 0.6% (6/890) among patients allocated to thrombolytic
therapy and 3.0% (27/886) in the control group. Thrombolytic
treatment was associated with a significant reduction of PE-related
mortality (OR: 0.29; 95% CI: 0.14–0.60, P, 0.001) and no hetero-
geneity was detected (I2 0%). No significant difference was found
Figure 2 Early mortality by pulmonary embolism severity, Forest plot.
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Table 2 Efficacy outcomes, subgroup analyses
All studies Studies includinga
High-risk PE
Intermediate-risk
PE
Low and
intermediate-risk PE
Group
difference
OR (95% CI) P-value I2 (%) OR (95% CI) OR (95% CI) OR (95% CI) P-value
Mortality 0.59 (0.36 to 0.96) 0.034 0 0.48 (0.20 to 1.15) 0.42 (0.17 to 1.03) 0.96 (0.41 to 2.24) 0.36
PE mortality 0.29 (0.14 to 0.60) ,0.001 0 0.15 (0.03 to 0.78) 0.17 (0.05 to 0.67) 0.63 (0.20 to 1.97) 0.23
Death or treatment
escalation
0.34 (0.22 to 0.52) ,0.001 0 0.18 (0.04 to 0.79) 0.37 (0.20 to 0.69) 0.35 (0.18 to 0.66) 0.67
PE recurrence 0.50 (0.27 to 0.94) 0.031 0 0.97 (0.31 to 2.98) 0.25 (0.06 to 1.03) 0.46 (0.17 to 1.21) 0.33
aNot exclusively.
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according to the thrombolytic regimen (P ¼ 0.61) or the severity
of PE (P ¼ 0.23).
Death or need for treatment escalation
This outcome was available in nine studies including 1639 patients
(Supplementary material online, Figure S2). It was pre-defined in
five studies (1474 patients)10,13,19,26,31 and obtained based on the
detailed description of complications in the remaining four studies
(185 patients).12,27 –29 Death or treatment escalation were reported
in 3.6% (29/808) of the patients allocated to thrombolytic therapy
and 10.2% (85/831) in the control group. Thrombolytic therapy
was associated with a significant reduction of this outcome
(OR: 0.34; 95% CI: 0.22–0.52, P, 0.001). The result was similar
when the analysis was restricted to the five studies in which the
outcome was pre-defined10,13,19,26,31 (OR: 0.37; 95% CI: 0.24–
0.59, P, 0.0001). No heterogeneity was detected (I2 ¼ 0%). No sig-
nificant difference was found according to the thrombolytic regimen
(P ¼ 0.54) or the severity of PE (P ¼ 0.67).
Pulmonary embolism recurrence
Pulmonary embolism recurrence was reported in 11 stu-
dies,8,10–13,18– 19,28,30– 32 including 1928 patients (Supplementary
material online, Figure S3). The reported incidence of PE recurrence
was 1.3% (13/966) among patients allocated to thrombolytic therapy
and 2.9% (28/962) in the control group. Thrombolytic therapy was
associated with a statistically significant reduction of PE recurrence
(OR; 0.50; 95% CI: 0.27–0.94, P ¼ 0.03). No heterogeneity was
detected (I2 ¼ 0%). No significant difference was found according to
the thrombolytic regimen (P ¼ 0.39) or the severity of PE (P ¼ 0.33).
Major bleeding
Major bleeding was reported in 12 studies (1935 patients) and was
present in 9.9% (96/974) of patients allocated to thrombolytic
therapy and 3.6% (35/961) of the control group. Thrombolytic
treatment was associated with a significantly increased risk of major
bleeding (OR: 2.91; 95% CI: 1.95–4.36, P, 0.0001; Figure 3). Low
amount of heterogeneity was detected (I2 ¼ 25%). Subgroup analysis
did not show any differences between studies using invasive vs. non-
invasive diagnostic procedures. Subgroup analysis based on thrombo-
lytic agent suggested a lower riskofmajorbleeding in studies using alte-
plase compared with tenecteplase (Table 3). Nevertheless, this
subgroup difference was not significant after exclusion of the study
by Konstantinides et al.31 which used a more restrictive definition of
major haemorrhage. Finally, the association between thrombolytic
therapy and the risk of major bleeding was lower in studies using an
upper age limit (OR: 1.13; 95% CI: 0.47–2.71) than in studies including
older patients (OR: 3.71; 95% CI: 2.32–5.92) (P ¼ 0.02).
Figure 3 Major bleeding by drug, Forest plot.
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Intracranial or fatal haemorrhage
Intracranial or fatal haemorrhagewas reported in 12 studies including
1864 patients (Supplementary material online, Figure S4). The
reported incidence of fatal or intracranial haemorrhage was 1.7%
(n ¼ 16/933) in the thrombolysis group and 0.3% (n ¼ 3/931) in
the control group. Thrombolytic treatment was associated with a
significantly increased risk of fatal or intracranial haemorrhage
(OR: 3.18; 95% CI: 1.25–8.11, P ¼ 0.008). Subgroup analysis based
on thrombolytic agent suggested a lower risk of intracranial or fatal
haemorrhage in studies using alteplase compared with tenecteplase
(Table 3). The risk of fatal or intracranial haemorrhage was lower in
studies with an upper age limit (OR: 1.82; 95% CI: 0.37–8.93) than
those without (OR: 4.11; 95% CI: 1.25–13.5), but this difference
was not statistically significant (P ¼ 0.42).
Other potential sources of heterogeneity
There were no significant differences between studies using a time
from the onset of symptoms superior or inferior to 1 week except
for the outcome major bleeding. The risk of major bleeding was
higher in studies using a longer time of symptoms before inclusion.
Similarly, no significant differences were observed according to the
length of follow-up except for the outcome major bleeding. The
risk of major bleeding was higher in studies using a shorter follow-up.
The resultsof these analysesareprovidedonSupplementarymaterial
online,Tables S4 and S5. Finally, the meta-regression of the logarithms
of the odds ratios over years of publication did not detect any
significant interaction between these variables for any of the out-
comes (Supplementary material online, Table S6).
Sensitivity analyses
Excluding studies one by one did not significantly alter the effect of
thrombolysis with regard to the overall mortality, but statistical signifi-
cance was lost after exclusion of the study by Jerjes-Sanchez et al.27
(OR: 0.66, 95% CI: 0.40–1.11, P ¼ 0.09) or the study by Fasullo
et al.13 (OR: 0.65, 95% CI: 0.39–1.08, P ¼ 0.12). Similarly, statistical
significance was lost after deletion of a single study12,13,18,19 for the
outcome PE recurrence without major alteration of the treatment
effect size (OR; 0.55). The outcomes of PE-related mortality and
death or treatment escalation were not sensitive to a specific study.
The study by Meyer et al.19 contributed importantly to the outcomes
of major bleeding and fatal or intracranial haemorrhage: the ORs
were reduced (1.66; 95% CI: 0.96–2.88 and 1.53; 95% CI: 0.48–4.87)
and statistical significance was lost after omission of this study.
The pooled ORs were robust regarding the continuity correction
for all outcomes except for intracranial or fatal haemorrhage: the OR
reached 4.67 (95% CI: 1.46–14.92, P ¼ 0.009) for a continuity cor-
rection of 0.1. The use of an exact method to combine odds
ratios across studies provided similar estimates except for
intracranial or fatal haemorrhage: the OR reached 5.18 (95% CI:
1.47–27.88, P, 0.004).
When only studies with good quality (Jadad score 4 or 5) were
combined, the OR for the outcome overall mortality was unchanged
(0.61; 95% CI: 0.36–1.06) but the statistical significance was lost
(P ¼ 0.08). The results were similar for the secondary outcomes.
Publication bias
The inspection of funnel plots revealed potential publication bias,
especially for PE recurrence and death or treatment escalation
(P ¼ 0.02 for both, Egger’s test). Missing studies for the funnel plots
to be symmetrical (trim and fill method) would be studies with low
precision and ORs in favour of controls. One missing study was
detected for the outcome overall mortality (Figure 4) (study symmet-
rical to Jerjes-Sanchez) and three studies for the outcome PE recur-
rence. If these missing studies were added, the ORs for the outcomes
overall mortality and PE-related mortality remained in favour of
thrombolytic treatment but were not significantly different from
1 (0.69, 95% CI: 0.40–1.19 and 0.84, 95% CI: 0.44–1.60). For the
other outcomes, the ORs were slightly modified and remained
significantly different from 1.
Figure 4 Early mortality, Funnel plot of included studies.
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Table 3 Safety outcomes, subgroup analyses
All studies Alteplase Tenecteplase Other
thrombolytics
Group
difference
OR (95% CI) P-value I2 (%) OR (95% CI) OR (95% CI) OR (95% CI) P-value
Major bleeding 2.91 (1.95 to 4.36) ,0.001 25 1.07 (0.43 to 2.62) 5.02 (2.72 to 9.26) 2.16 (1.03 to 4.54) 0.02
Fatal/intracranial
haemorrhage
3.18 (1.25 to 8.11) 0.008 0 1.09 (0.27 to 4.40) 7.32 (1.64 to 32.63) NA 0.07
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Discussion
Evidence from currently available randomized trials suggests that
thrombolytic treatment reduces overall mortality of patients with
acute PE. Although the estimated treatment effect corresponded
to a 41% relative risk reduction of overall mortality, the benefit of
thrombolytic therapy for patients with acute PE could not be defin-
itely established. This observation deserves several comments:
First, the robustness of our primary result was limited, since
statistical significance was lost after exclusion of the study by
Jerjes-Sanchez et al.27 This small size, open-label trial included only
patients with high-risk PE and was limited by gross imbalance
between-groups, the four patients allocated to heparin treatment
having been admitted for an acute episode of unstable PE despite pre-
vious therapeutic anticoagulation. Nevertheless, even afterexclusion
of this trial, a trend towards decreased all-cause mortality was
observed (OR: 0.65; 95% CI: 0.39–1.08). Second, early mortality is
relatively uncommon among patients with acute PE, particularly
those with non-high-risk PE. Therefore, considering a mortality of
3.9% in the control group, a 41% relative risk reduction would lead
to an absolute mortality risk reduction of only 1.6% in our overall
population. Our subgroup analyses suggest a possible correlation
between PE severity and treatment effect. The pooled ORs were
similar in studies including (not exclusively) high-risk PE and studies
restricted to intermediate-risk PE with an estimated mortality risk re-
duction 55%, whereas the OR was suggestive of an absence of
benefit in studies including only low- and intermediate-risk PE.
However, these subgroup analyses were limited by a lack of statistical
power and some between-groups overlap in terms of PE severity.
On the other hand, the mortality benefit of thrombolytic therapy
may be underestimated because of the possibility to administer
rescue thrombolysis to clinically deteriorating patients allocated to
anticoagulant therapy; it is likely that some of these patients might
have died without rescue treatment. Rescue thrombolysis was actu-
ally administered in 4.6 and 23% of control patients in the two largest
randomized trials in this meta-analysis,19,31 and its use was restricted
to patients with secondary haemodynamic collapse in PEITHO.19
However and despite reasonable equipoise on the efficacy of
thrombolysis in intermediate-risk PE, a randomized trial not allowing
for emergency escalation of treatment (such as rescue thrombolysis)
would certainly be considered ethically unacceptable. When treat-
ment escalation was combined with all-cause mortality, the pooled
OR was slightly lower and statistically significant in all PE severity sub-
groups and sensitivity analyses.
The benefits of thrombolytic therapy must be weighed against the
risk of haemorrhagic complications. The rate of major bleeding com-
plications reported in our meta-analysis in patients allocated to
thrombolytic therapy (9.9%) is similar to that reported by Wan
et al.15 (9.1%) and Dong et al.14 (10.4%). In contrast to our
meta-analysis, these previous reports failed to demonstrate a signifi-
cant association between thrombolytic therapy and major bleeding.
This difference appears to result mainly from the inclusion of the
PEITHO trial in our meta-analysis, which included more patients
than all other studies together and a higher proportion of elderly
patients with a higher bleeding risk. Interestingly, our subgroup ana-
lysis suggested a higher risk for both major bleeding and fatal or intra-
cranial haemorrhage in patients treated by tenecteplase compared
with those treated with alteplase, probably because two of the
three studies using tenecteplase10,19 had the oldest populations of
all 15 studies included in this meta-analysis. As also previously
reported by others,33 the inclusion of older patients was associated
with an increased risk of bleeding in our analysis (Supplementary ma-
terial online, Table S3).
Given the non-negligible risks of systemic thrombolytic treatment
and the relatively low risk of early mortality among patients
with acute PE, research has recently focused on minimization of
thrombolysis-related risks by dose reduction,18 a strategy of catheter-
delivered, ultrasound-assisted administration of thrombolytic treat-
ment,34 and the identification of intermediate-risk patients with a
potentially favourable risk-to-benefit ratio for thrombolytic therapy.
Identification of intermediate-risk patients based on RVD and/or
laboratory biomarkers was performed in three studies10,13,19 with a
trend towards reduced mortality of borderline significance. Right
ventricular dysfunction and laboratory markers of myocardial injury
have been widely validated as adverse prognostic markers in patients
with PE.35–39 However, the observed mortality rate in the control
group (2.6%) in studies including intermediate-risk PE10,13,19 was
lower than reported in large cohort studies of unselected PE
patients3,40 whichmayhave limited theconclusivenessof this subgroup
analysis. This low mortality rate might be explained by the selection
criteria of randomized trials and probably also by the close monitoring
of the patients included in the trials on intermediate-riskPE. Sincemost
of the studies included PE patients with a wide spectrum of severity,
an individual data meta-analysis is warranted to specifically assess
treatment benefit in patients with intermediate risk PE, or to identify
a subgroup of patients with a favourable risk–benefit ratio.
The present study has several potential limitations. As previously
discussed, and despite the inclusion of large recent randomized
trials, the power of our analysis remains low because of the low inci-
dence of the primary outcome leading to the loss of statistical signifi-
cance in some subgroup and sensitivity analyses and to a loss of
precision of treatment effect estimate in subgroup analyses Neverthe-
less, the present meta-analysis included more than twice as many
patients as previous reports allowing for a more precise estimate of
treatment effect and the selection of a robust primary outcome.
Previous meta-analyses frequently reported combined outcomes of
variable clinical significance,15 complicating the risk-to-benefit estima-
tion of thrombolytic therapy. Systematic reviews and meta-analyses
depend on the quality of included studies. Although the quality of
the majority of the studies included in this review was considered
good, important differences in inclusion criteria, thrombolytic regi-
mens and dosing, and PE severity were present among studies, limiting
the generalization of our conclusions.
Conclusion
Systemic thrombolytic therapy is associated with a significant reduc-
tion of overall mortality in patients with PE, but this reduction is not
statistically significant after exclusion of studies including high-risk PE.
Thrombolytic therapy significantly reduces PE-related mortality, the
combined outcome of death or treatment escalation and symptom-
atic PE recurrence, but is associated with an increase in fatal, intracra-
nial, or major haemorrhage. Owing to this narrow risk–benefit ratio,
furtheranalysis basedon individual data iswarranted to identifywhich
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subgroup of patients with non-high-risk PE might benefit from
thrombolytic therapy.
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